In vitro experiments have shown that bosutinib has antiproliferative activity against multiple BCR::ABL1-positive leukemia cell lines as well as the ability to block BCR::ABL1 phosphorylation at sub-micromolar concentrations [132]. Here, ABL1 is linked to leukemia.